REBECCA Real-world Early BrEast CanCer mAnagement

An observational study of Breast Cancer, run by AstraZeneca at 58 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Trial summary

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Breast Cancer
How many people: 126 participants
Where: 58 sitesFrance
Study dates: 30 Dec 2024to 31 Jan 2028
Phase: Observational
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Study population: Patients will be recruited from about 60 participating sites to reach the target of 126 subjects, with a maximum of 60% of subtype TN overall.

Who may be able to join

Male or female aged ≥ 18 years
Patient diagnosed with HER2-negative eBC
Patient about to be initiated with adjuvant Olaparib at their physician's discretion
Patient has been informed and does not object to participation in the study.

Who cannot join

Patient not consenting to participate.
Patients included in the Early Access Program

Trial locations and contacts

58 sites in 1 country. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

City, postcode or hospital

Sites recruiting now only

58 sites in 1 country

France58 sites, 58 recruiting

Research Site
Agen, New Aquitaine, 47923
Not yet recruiting
Research Site
Argenteuil, Île-de-France Region, 95107
Not yet recruiting
Research Site
Avignon, Provence-Alpes-C Te d'Azur, 84918
Not yet recruiting
Research Site
Beauvais, Hauts-de-France, 60021
Recruiting
Research Site
Beuvry, Hauts-de-France, 62660
Recruiting
Research Site
Bezannes, Grand Est, 51430
Recruiting
Research Site
Béziers, Occitanie, 34500
Not yet recruiting
Research Site
Caen, Normandy, 14000
Recruiting
Research Site
Chambray-lès-Tours, Centre-Val de Loire, 37170
Recruiting
Research Site
Champigny-sur-Marne, Île-de-France Region, 94507
Recruiting
Research Site
Clermont-Ferrand, Auvergne-Rh ne-Alpes, 63050
Recruiting
Research Site
Compiègne, Hauts-de-France, 60204
Not yet recruiting
Research Site
Creil, Hauts-de-France, 60109
Not yet recruiting
Research Site
Dechy, Hauts-de-France, 59187
Recruiting
Research Site
Dijon, Bourgogne-Franche-Comt, 21079
Not yet recruiting
Research Site
FORT de France Cedex, Martinique, 97261
Not yet recruiting
Research Site
Fréjus, Provence-Alpes-C Te d'Azur, 83608
Not yet recruiting
Research Site
Gleizé, Auvergne-Rh ne-Alpes, 69400
Recruiting
Research Site
Grenoble, Auvergne-Rh ne-Alpes, 38000
Not yet recruiting
Research Site
Haguenau, Grand Est, 67504
Not yet recruiting
Research Site
Le Blanc-Mesnil, Île-de-France Region, 93150
Not yet recruiting
Research Site
Libourne, New Aquitaine, 33505
Not yet recruiting
Research Site
Lille, Hauts-de-France, 59020
Not yet recruiting
Research Site
Lille, Hauts-de-France, 59037
Not yet recruiting
Research Site
Limoges, New Aquitaine, 87042
Not yet recruiting
Research Site
Lyon, Auvergne-Rh ne-Alpes, 69317
Recruiting
Research Site
Marseille, Provence-Alpes-C Te d'Azur, 13385
Not yet recruiting
Research Site
Metz-Tessy, Auvergne-Rh ne-Alpes, 74370
Recruiting
Research Site
Montpellier, Occitanie, 34070
Recruiting
Research Site
Montpellier, Occitanie, 34298
Recruiting
Research Site
Nancy, Grand Est, 54100
Recruiting
Research Site
Nantes, Pays de la Loire Region, 44202
Not yet recruiting
Research Site
Nice, Provence-Alpes-C Te d'Azur, 06105
Not yet recruiting
Research Site
Nîmes, Occitanie, 30900
Recruiting
Research Site
Osny, Île-de-France Region, 95520
Recruiting
Research Site
Paris, Île-de-France Region, 75651
Recruiting
Research Site
Paris, Île-de-France Region, 75674
Recruiting
Research Site
Paris, Île-de-France Region, 75908
Not yet recruiting
Research Site
Paris, Île-de-France Region, 75970
Not yet recruiting
Research Site
Périgueux, New Aquitaine, 24000
Recruiting
Research Site
Perpignan, Occitanie, 66046
Recruiting
Research Site
Plérin, Brittany Region, 22190
Recruiting
Research Site
Poitiers, New Aquitaine, 86021
Recruiting
Research Site
Rennes, Brittany Region, 35042
Not yet recruiting
Research Site
Rouen, Normandy, 76175
Recruiting
Research Site
Saint-Brieuc, Brittany Region, 22027
Not yet recruiting
Research Site
Saint-Doulchard, Centre-Val de Loire, 18230
Recruiting
Research Site
Saint-Etienne, Auvergne-Rh ne-Alpes, 42030
Not yet recruiting
Research Site
Saint-Grégoire, Brittany Region, 35768
Recruiting
Research Site
Saint-Martin-Boulogne, Hauts-de-France, 62280
Not yet recruiting
Research Site
Saint-Pierre-des-Corps, La R Union, 97448
Not yet recruiting
Research Site
Saint-Priest-en-Jarez, Auvergne-Rh ne-Alpes, 42271
Not yet recruiting
Research Site
Salouël, Hauts-de-France, 80054
Recruiting
Research Site
Sarcelles, Île-de-France Region, 95200
Recruiting
Research Site
Thonon-les-Bains, Auvergne-Rh ne-Alpes, 74200
Recruiting
Research Site
Toulouse, Occitanie, 31300
Recruiting
Research Site
Valence, Auvergne-Rh ne-Alpes, 26000
Recruiting
Research Site
Valence, Auvergne-Rh ne-Alpes, 26953
Not yet recruiting

Other trials in France

About this study

Official title: REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

Read the detailed description

The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.

Conditions: Breast Cancer
Medical subject headings: Breast Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

Proportion of patients who receive Olaparib for the full treatment duration
The primary outcome is the evaluation of the proportion of patients who receive Olaparib for the full treatment duration, described as 12 months of treatment.
Measured: 18 months after inclusion

Secondary outcomes (4)

BRCA characteristics: Mutation type
Regarding BRCA characteristics: Mutation type: Tumoral (if only tumoral testing performed), somatic, germline.
Measured: 18 months after inclusion
Type of variants
Type of variants: BRCA1 and/or BRCA2, PALB2 mutation, presence of other HRR gene mutations, presence of other mutations
Measured: 18 months after inclusion
Medical history
Family and personal history of cancer/type
Measured: 18 months after inclusion
Time to Olaparib treatment discontinuation
Time to Olaparib Treatment Discontinuation (TTD) or death
Measured: 18 months after inclusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 Dec 202431 Jan 2028

First posted4 Mar 2025
Study start30 Dec 2024
Primary completion31 Jan 2028 (estimated)
Study completion31 Jan 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Breast CancerStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Cohort
Time perspective: Prospective
Enrolment: 126 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06856343
Sponsor's protocol ID: D0817R00068
Acronym: REBECCA
Status last verified: Aug 2026
First submitted: 12 Dec 2024
Last updated: 25 Aug 2026
Results posted: No

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8

All Breast Cancer trials

Study at a glance

From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients
ClinicalTrials.gov ID: NCT06856343
Acronym / sponsor ID: REBECCA / D0817R00068
Conditions: Breast Cancer
Study type: Observational
Recruitment status: Recruiting
Enrolment: 126 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 30 Dec 2024 (actual)
Primary completion: 31 Jan 2028 (estimated)
Study completion: 31 Jan 2028 (estimated)
First posted: 4 Mar 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

Detailed description

The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.

Study design

Observational model: Cohort
Time perspective: Prospective

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult
Study population: Patients will be recruited from about 60 participating sites to reach the target of 126 subjects, with a maximum of 60% of subtype TN overall.

Key inclusion criteria (4 listed)

Male or female aged ≥ 18 years
Patient diagnosed with HER2-negative eBC
Patient about to be initiated with adjuvant Olaparib at their physician's discretion
Patient has been informed and does not object to participation in the study.

Key exclusion criteria (2 listed)

Patient not consenting to participate.
Patients included in the Early Access Program

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Primary outcome

Proportion of patients who receive Olaparib for the full treatment duration
Time frame: 18 months after inclusion
The primary outcome is the evaluation of the proportion of patients who receive Olaparib for the full treatment duration, described as 12 months of treatment.

4 secondary outcomes

BRCA characteristics: Mutation type
Time frame: 18 months after inclusion
Type of variants
Time frame: 18 months after inclusion
Medical history
Time frame: 18 months after inclusion
Time to Olaparib treatment discontinuation
Time frame: 18 months after inclusion

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.

Related trials for Breast Cancer

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

58 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Breast Cancer, run by AstraZeneca at 58 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 58 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of patients who receive Olaparib for the full treatment duration (time frame: 18 months after inclusion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06856343.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.